Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07391774CT.gov Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | — | Recruiting | — | — | — |
NCT07610720CT.gov Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT07395336CT.gov Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE) | — | Recruiting | — | — | — |
NCT07483307CT.gov A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer | — | Recruiting | — | — | — |
NCT07349069CT.gov A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer | — | Recruiting | — | — | — |
NCT07400523CT.gov Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy | — | Recruiting | — | — | — |
NCT07299890CT.gov An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07369505CT.gov Sapu003 in Advanced mTOR-sensitive Solid Tumors | — | Recruiting | — | — | — |
NCT07071038CT.gov Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients | — | Recruiting | — | — | — |
NCT07163481CT.gov A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | — | Not Yet Recruiting | — | — | — |
Show 129 more trialsShow fewer
NCT07101159CT.gov Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients | — | Not Yet Recruiting | — | — | — |
NCT07062965CT.gov A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | — | Recruiting | — | — | — |
NCT07024173CT.gov A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT06630325CT.gov A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | — | Terminated | — | — | — |
NCT07190443CT.gov Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) | — | Recruiting | — | — | — |
NCT06428396CT.gov Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | — | Recruiting | — | — | — |
NCT06680921CT.gov A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | — | Recruiting | — | — | — |
NCT06806930CT.gov Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) | — | Recruiting | — | — | — |
NCT06492616CT.gov A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | — | Recruiting | — | — | — |
NCT06656624CT.gov Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) | — | Recruiting | — | — | — |
NCT06380751CT.gov Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06179303CT.gov Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06957379CT.gov Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy | — | Active Not Recruiting | — | — | — |
NCT05827081CT.gov Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | — | Recruiting | — | — | — |
NCT06105632CT.gov A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | — | Active Not Recruiting | — | — | — |
NCT05512364CT.gov Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | — | Recruiting | — | — | — |
NCT06016738CT.gov OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05952557CT.gov An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | — | Recruiting | — | — | — |
NCT06001762CT.gov TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05894239CT.gov A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05826964CT.gov Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05891093CT.gov Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | — | Recruiting | — | — | — |
NCT05861830CT.gov Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) | — | Recruiting | — | — | — |
NCT05768139CT.gov First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06009627CT.gov Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients | — | Completed | — | — | — |
NCT05774951CT.gov A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | — | Recruiting | — | — | — |
NCT05079360CT.gov Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | — | Withdrawn | — | — | — |
NCT05573126CT.gov Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | — | Recruiting | — | — | — |
NCT05645536CT.gov Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | — | Enrolling By Invitation | — | — | — |
NCT04997798CT.gov Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | — | Unknown | — | — | — |
NCT05463601CT.gov Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05296798CT.gov A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT05431504CT.gov The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | — | Not Yet Recruiting | — | — | — |
NCT05472792CT.gov Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy | — | Recruiting | — | — | — |
NCT05307705CT.gov A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05065411CT.gov Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT04869943CT.gov Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT04961996CT.gov A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT04965688CT.gov Biology Guided Therapy for Breast Cancer for ER Positive | — | Terminated | — | — | — |
NCT04906395CT.gov Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04858516CT.gov Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer | — | Unknown | — | — | — |
NCT04852081CT.gov Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | — | Unknown | — | — | — |
NCT04584853CT.gov PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | — | Active Not Recruiting | — | — | — |
NCT04300790CT.gov Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | — | Completed | — | — | — |
NCT04460430CT.gov Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT04465097CT.gov Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer | — | Completed | — | — | — |
NCT03554044CT.gov T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | — | Completed | — | — | — |
NCT04059484CT.gov Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | — | Terminated | — | — | — |
NCT02917005CT.gov PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer | — | Unknown | — | — | — |
NCT03874325CT.gov Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer | — | Terminated | — | — | — |
NCT03691493CT.gov Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | — | Completed | — | — | — |
NCT04012918CT.gov Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study | — | Unknown | — | — | — |
NCT03538171CT.gov Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT03555877CT.gov Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer | — | Completed | — | — | — |
NCT03308201CT.gov Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer | — | Completed | — | — | — |
NCT04659551CT.gov Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | — | Completed | — | — | — |
NCT03291886CT.gov Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | — | Completed | — | — | — |
NCT03312738CT.gov A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | — | Completed | — | — | — |
NCT02990845CT.gov Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03179904CT.gov TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03125746CT.gov A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors | — | Unknown | — | — | — |
NCT02997995CT.gov Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure | — | Completed | — | — | — |
NCT02476786CT.gov Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | — | Recruiting | — | — | — |
NCT02894398CT.gov Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | — | Completed | — | — | — |
NCT02833155CT.gov Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02820961CT.gov Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | — | Completed | — | — | — |
NCT02732119CT.gov Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. | — | Completed | — | — | — |
NCT02592746CT.gov A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | — | Unknown | — | — | — |
NCT02188745CT.gov ER Reactivation Therapy for Breast Cancer | — | Completed | — | — | — |
NCT02532400CT.gov Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients | — | Terminated | — | — | — |
NCT02404051CT.gov Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT02623751CT.gov Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer | — | Completed | — | — | — |
NCT02344472CT.gov Detect V / CHEVENDO (Chemo vs. Endo) | — | Active Not Recruiting | — | — | — |
NCT02387099CT.gov Dose EScalation Induction of EvERolimus | — | Completed | — | — | — |
NCT02291913CT.gov Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT02248571CT.gov Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | — | Completed | — | — | — |
NCT02069093CT.gov Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | — | Completed | — | — | — |
NCT02115282CT.gov Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic | — | Active Not Recruiting | — | — | — |
NCT02028507CT.gov Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | — | Completed | — | — | — |
NCT02109913CT.gov Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane | — | Unknown | — | — | — |
NCT02049957CT.gov Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02028364CT.gov Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women | — | Completed | — | — | — |
NCT01989780CT.gov Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | — | Completed | — | — | — |
NCT02007512CT.gov Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | — | Completed | — | — | — |
NCT02023359CT.gov Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01950182CT.gov Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | — | Completed | — | — | — |
NCT01674140CT.gov S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01857193CT.gov Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT01870505CT.gov BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01783444CT.gov A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | — | Completed | — | — | — |
NCT01720602CT.gov Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | — | Completed | — | — | — |
NCT02549430CT.gov To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | — | Completed | — | — | — |
NCT01627067CT.gov Exemestane-RAD001-Metformin | — | Terminated | — | — | — |
NCT01626222CT.gov 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01594398CT.gov Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01597193CT.gov Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | — | Completed | — | — | — |
NCT01240941CT.gov Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer | — | Withdrawn | — | — | — |
NCT01385280CT.gov Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer | — | Completed | — | — | — |
NCT01153672CT.gov Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | — | Completed | — | — | — |
NCT01149356CT.gov RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT01234857CT.gov A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | — | Completed | — | — | — |
NCT00905021CT.gov Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00972023CT.gov DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer | — | Terminated | — | — | — |
NCT01005641CT.gov ELBA: Exemestane and Lapatinib in Advanced Breast Cancer | — | Withdrawn | — | — | — |
NCT01004081CT.gov Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | — | Completed | — | — | — |
NCT01896050CT.gov Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer | — | Completed | — | — | — |
NCT00863655CT.gov Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole | — | Completed | — | — | — |
NCT00931450CT.gov Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer | — | Unknown | — | — | — |
NCT00767520CT.gov Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer | — | Completed | — | — | — |
NCT00793546CT.gov Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer | — | Terminated | — | — | — |
NCT00728949CT.gov A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | — | Completed | — | — | — |
NCT00676663CT.gov Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT00674557CT.gov Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer | — | Terminated | — | — | — |
NCT00688194CT.gov Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | — | Unknown | — | — | — |
NCT00659373CT.gov Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 | — | Completed | — | — | — |
NCT00573755CT.gov Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00508586CT.gov PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00516542CT.gov Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00432172CT.gov Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients | — | Completed | — | — | — |
NCT00194792CT.gov Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | — | Terminated | — | — | — |
NCT00066690CT.gov Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | — | Completed | — | — | — |
NCT00066703CT.gov Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | — | Completed | — | — | — |
NCT00066807CT.gov Premenopausal Endocrine Responsive Chemotherapy Trial | — | Terminated | — | — | — |
NCT00525096CT.gov Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00201773CT.gov Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer | — | Completed | — | — | — |
NCT01831076CT.gov Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | — | Completed | — | — | — |
NCT00010010CT.gov Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00200174CT.gov Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease | — | Completed | — | — | — |
NCT01240928CT.gov MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Exemestane (this asset) | National Cancer Institute (NCI) | Approved | BB · 69 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Vitamin D | University of Illinois at Chicago | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Adriamycin | George Washington University | P4 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Peg-Rhg-Csf | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Exemestane
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Estrogen-Receptor Positive Breast Cancer | — | P4 | BBB · 72 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Breast Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Exemestane in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/exemestane-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →